<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="199350">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00495274</url>
  </required_header>
  <id_info>
    <org_study_id>OXS105205</org_study_id>
    <nct_id>NCT00495274</nct_id>
  </id_info>
  <brief_title>Bioequivalence and Food Effect Study in Healthy Volunteers</brief_title>
  <official_title>A Single-centre, Open-label, Randomized, Single-dose, 6-way Crossover Study to Investigate the Pharmacokinetics, Safety and Tolerability of 6 Different Formulations of SB-649868 30 mg (Part A) and the Effect of Food on the Selected Formulation of SB-649868 Pharmacokinetic (Part B) in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to select the formulation with the optimal pharmacokinetic
      profile for an hypnotic drug to further develop in the market.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single-centre, open-label, randomized, single-dose, 6-way crossover study to investigate
      the pharmacokinetics, safety and tolerability of 6 different formulations of SB-649868 30 mg
      (Part A) and the effect of food on the selected formulation of SB-649868 pharmacokinetic
      (Part B) in healthy male volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>-Part A: SB-649868 levels of 6 formulation predose, 0.5, 1, 1.5, 2,3,4,5,6,8,12 and 24hours post-dose</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2,3,4,5,6,8,12 and 24hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>-Part B: SB-649868 levels of selected formulation after food at the same timepoints as in Part A</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2,3,4,5,6,8,12 and 24hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>-AE, Lab values and cardiovascular monitoring throughout study participation</measure>
    <time_frame>throughout study participation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Romberg heel-to-toe test at discharge</measure>
    <time_frame>at discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Cognitive functions predose, 0.5, 1, 2, 4, 6 hours post-dose</measure>
    <time_frame>predose, 0.5, 1, 2, 4, 6 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic endpoint: Bond Lader Visual Analogue Scale (VAS) score</measure>
  </secondary_outcome>
  <enrollment type="Actual">16</enrollment>
  <condition>Sleep Initiation and Maintenance Disorders</condition>
  <condition>Insomnia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-649868</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy adult male subjects aged between 18 and 65 years of age inclusive.

          -  Body weight and BMI within the protocol ranges.

          -  Healthy as determined by a responsible physician, based on a medical evaluation
             including history, physical examination, laboratory tests, cardiac monitoring.

          -  Circulating levels of LH, FSH and testosterone within the normal reference range.

          -  Signed and dated written informed consent.

          -  The subject is able to understand and comply with protocol requirements, instructions
             and protocol-stated restrictions.

        Exclusion criteria:

          -  Positive pre-study urine drug screen and alcohol breath test.

          -  Positive pre-study Hepatitis B surface antigen, Hepatitis C antibody, or HIV Â½
             result.

          -  Abuse of alcohol as per protocol criteria.

          -  Consumption of prohibited food and drink as per protocol.

          -  Subject who is not prepared to eat the standard meals provided by the site.

          -  Use of prescription or non-prescription drugs 1 or 2 weeks before the first dose of
             study medication.

          -  Where participation in study would result in donation of blood in excess of 500mL
             within a 56 day period.

          -  History or presence of allergy to the study drug or drugs of this class, or a history
             of other allergy.

          -  Smoking history in the last three months as per protocol.

          -  An unwillingness of male subjects to follow contraception methods as per protocol.

          -  History or presence of significant psychiatric, respiratory or gastrointestinal
             illnesses, hepatic or renal diseases or other condition known to interfere with the
             absorption, distribution, metabolism or excretion of drugs.

          -  The subject is unable or unwilling to abstain from strenuous physical activity in the
             48 hours before screening and in the 48 hours before and the 48 hours after the
             treatment period.

          -  Current or previous (within 6 months) participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Verona</city>
        <state>Veneto</state>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 19, 2017</lastchanged_date>
  <firstreceived_date>June 29, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalent</keyword>
  <keyword>pharmacodynamic</keyword>
  <keyword>Reference formulation</keyword>
  <keyword>5 new formulation</keyword>
  <keyword>Food effect</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
